Clinical trials offer patients the very latest in cancer care, while giving physicians and researchers the opportunity to study the effectiveness of the treatment. The Capital Health Center for Oncology participates in many National Cancer Institute, University and Pharmaceutical Phase III clinical trials. Our oncologists and research nurses carefully review the study criteria, potential benefits, risks, and other considerations with eligible patients before enrolling in a clinical study. The staff in our Clinical Research Department will carefully monitor you throughout the clinical trial and answer any questions you may have about the trial.
NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Vs. Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
A071102: A Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation (currently on sponsor initiated interim hold since 10/2016)
A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) who Have positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (Pending IRB approval)
NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Pending IRB approval)
A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
NRG BR-003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plust Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer (pending CHS IRB & CIRB approval)
NSABP B-55: A Randomized, Double Blind, Parallel Group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA ½ Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Tretment and Neoadjuvant or Adjuvant Chemotherapy (pending with CHS IRB & CIRB approval)
EAY131: Molecular Analysis for Therapy Choice (MATCH) – Patients enrolled in study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment. Patients with hystologically documented solid tumors and lymphomas whose disease has progressed following at least one line of standard systemic therapy or for whom no standard therapy exists will be registered on the screening step to undergo tumor biopsy and analysis.
RTOG 0631: Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis
- Radiation Oncology Studies - Establishing an anticipatory model for anxiety and depression through a screening tool for first-time radiation oncology patients
- Rutgers Cancer Institute of New Jersey – African American Woman’s Circle of Health Breast Cancer Research Study
- Dana-Faber/Brigham and Woman’s Cancer Center (Dr. Geoffrey Oxnard) – INHERIT EGFR (Genetic Mutation T790M Lung Registry Study)